IRON CHELATION THERAPY IN TRANSFUSION-DEPENDENT MYELODYSPLASTIC SYNDROMES. RETROSPECTIVE STUDY OF 53 PATIENTS IN A SINGLE INSTITUTION

被引：0
|
作者：
Finelli, C. [1 ]
Clissa, C. [2 ]
Barraco, M. [1 ]
De Maio, C. [1 ]
Fogli, M. [1 ]
Stanzani, M. [1 ]
Parisi, S. [1 ]
Paolini, S. [1 ]
Bosi, C. [3 ]
Cavo, M. [1 ]
机构：
[1] St Orsola Marcello Malpighi Hosp, Ist Ematol, Bologna, Italy
[2] Osped S Salvatore, Ematol, Bologna, Italy
[3] Osped Guglielmo de Saliceto, Ematol, Piacenza, Italy
来源：
HAEMATOLOGICA | 2017年 / 102卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
P015
引用
收藏
页码：57 / 57
页数：1
相关论文
共 50 条
  • [31] Rationale for Therapy Discontinuation in Patients with Lower-Risk Transfusion-Dependent Myelodysplastic Syndromes (MDS)
    Gerds, Aaron T.
    Gupta, Shaloo
    Binder, Gary
    Sekeres, Mikkael A.
    Nazha, Aziz
    Carraway, Hetty E.
    Hawthorne, Stephanie
    King-Concialdi, Kristen
    McGuire, Michael
    [J]. BLOOD, 2016, 128 (22)
  • [32] EFFECT OF CHELATION ON CARDIAC IRON OVERLOAD IN PATIENTS WITH TRANSFUSION-DEPENDENT THALASSEMIA
    Pines, Morgan
    Sheth, Sujit
    Kleinert, Dorothy
    [J]. PEDIATRIC BLOOD & CANCER, 2022, 69
  • [33] Evaluation of cardial iron deposition by T2 MRI in transfusion dependent patients with myelodysplastic syndromes.
    Deplano, Simona
    Di Tucci, Anna
    Matta, Gildo
    Agus, Annalisa
    Gabbas, Attilio
    Murru, Roberta
    Angelucci, Emanuele
    [J]. BLOOD, 2006, 108 (11) : 753A - 753A
  • [34] Efficacy and safety of deferasirox (Exjade®) in chelation-naive and previously chelated patients with transfusion-dependent myelodysplastic syndromes (MDS)
    Schmid, M.
    Guerci-Bresler, A.
    Della Porta, M.
    Taylor, K.
    Habr, D.
    Domokos, G.
    Roubert, B.
    Rose, C.
    Gattermann, N.
    [J]. LEUKEMIA RESEARCH, 2009, 33 : S141 - S142
  • [35] Geographical Differences In Transfusion and Iron Chelation Practices In 1558 Patients with Transfusion-Dependent Anemias
    Viprakasit, Vip
    Gattermann, Norbert
    Lee, Jong Wook
    Porter, John B.
    Taher, Ali
    Habr, Dany
    Roubert, Bernard
    Domokos, Gabor
    Cappellini, Maria Domenica
    [J]. BLOOD, 2010, 116 (21) : 1733 - 1734
  • [36] Consequences and costs of noncompliance with iron chelation therapy in patients with transfusion-dependent thalassemia: a literature review
    Delea, Thomas E.
    Edelsberg, John
    Sofrygin, Oleg
    Thomas, Simu K.
    Baladi, Jean-Francois
    Phatak, Pradyumna D.
    Coates, Thomas D.
    [J]. TRANSFUSION, 2007, 47 (10) : 1919 - 1929
  • [37] IRON CHELATION THERAPY IMPROVES OXIDATIVE DNA DAMAGE IN HEMATOPOIETIC CELLS DERIVED FROM TRANSFUSION-DEPENDENT MYELODYSPLASTIC SYNDROME
    Kobune, Masayoshi
    Kikuchi, Shohei
    Iyama, Satoshi
    Takada, Kohichi
    Murase, Kazuyuki
    Ono, Kaoru
    Horiguchi, Hiroto
    Kamihara, Yusuke
    Hayashi, Tsuyoshi
    Sato, Tsutomu
    Miyanishi, Koji
    Sato, Yasushi
    Takimoto, Rishu
    Kato, Junji
    [J]. AMERICAN JOURNAL OF HEMATOLOGY, 2013, 88 (05) : E98 - E98
  • [38] IRON CHELATION-THERAPY WITH DEFEROXAMINE FOR TRANSFUSION-DEPENDENT REFRACTORY-ANEMIA
    FRAME, JN
    CHIKKAPPA, G
    [J]. BLOOD, 1994, 84 (10) : A547 - A547
  • [39] Cost-effectiveness analysis of oral iron chelation therapy with deferasirox (Exjade®, ICL670) versus infusional chelation therapy with deferoxamine in patients with transfusion-dependent myelodysplastic
    Delea, TE
    Thomas, SK
    Baladi, JF
    Phatak, PD
    [J]. BLOOD, 2005, 106 (11) : 484B - 485B
  • [40] THE USE OF IRON CHELATION THERAPY FOR TRANSFUSION DEPENDENT MYELODYSPLASTIC SYNDROME PATIENTS: A CROSS-SECTIONAL STUDY IN BELGIUM
    Delforge, M.
    Selleslag, D.
    Triffet, A.
    Mineur, P.
    Beguin, Y.
    Noens, L.
    Pluymers, W.
    Ravoet, C.
    [J]. HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2009, 94 : 325 - 326
12345